Noncanonical roles of p53 in cancer stemness and their
implications in sarcomas

J 2022

Noncanonical roles of p53 in cancer stemness and their implications in sarcomas

CURYLOVÁ, Lucie; Helena RAMOS; Lucília SARAIVA a Jan ŠKODA

Základní údaje

Originální název

Noncanonical roles of p53 in cancer stemness and their implications in sarcomas

Autoři

CURYLOVÁ, Lucie; Helena RAMOS; Lucília SARAIVA a Jan ŠKODA

Vydání

Cancer letters, Elsevier Ireland Ltd, 2022, 0304-3835

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 9.700

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/22:00125082

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

p53; Sarcoma; Mesenchymal stem cells; Cancer stem cells; p53-targeted therapy

Štítky

14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 6. 12. 2021 13:10, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Impairment of the prominent tumor suppressor p53, well known for its canonical role as the "guardian of the genome", is found in almost half of human cancers. More recently, p53 has been suggested to be a crucial regulator of stemness, orchestrating the differentiation of embryonal and adult stem cells, suppressing reprogramming into induced pluripotent stem cells, or inhibiting cancer stemness (i.e., cancer stem cells, CSCs), which underlies the development of therapy-resistant tumors. This review addresses these noncanonical roles of p53 and their implications in sarcoma initiation and progression. Indeed, dysregulation of p53 family proteins is a common event in sarcomas and is associated with poor survival. Additionally, emerging studies have demonstrated that loss of wild-type p53 activity hinders the terminal differentiation of mesenchymal stem cells and leads to the development of aggressive sarcomas. This review summarizes recent findings on the roles of aberrant p53 in sarcoma development and stemness and further describes therapeutic approaches to restore normal p53 activity as a promising anti-CSC strategy to treat refractory sarcomas.

Návaznosti

NU20J-07-00004, projekt VaV

Název: Faktory kmenovosti a proteiny rodiny p53 u sarkomů dětského věku: Dysregulovaná transkripční síť jako potenciální cíl terapie

Investor: Ministerstvo zdravotnictví ČR, Faktory kmenovosti a proteiny rodiny p53 u sarkomů dětského věku: Dysregulovaná transkripční síť jako potenciální cíl terapie, Podprogram 2 - juniorský - výzkumníci do 35 let

Citovat

CURYLOVÁ, Lucie; Helena RAMOS; Lucília SARAIVA a Jan ŠKODA. Noncanonical roles of p53 in cancer stemness and their implications in sarcomas. Cancer letters. Elsevier Ireland Ltd, 2022, roč. 525, January, s. 131-145. ISSN 0304-3835. Dostupné z: https://doi.org/10.1016/j.canlet.2021.10.037.

@article{1807837,
   author = {Curylová, Lucie and Ramos, Helena and Saraiva, Lucília and Škoda, Jan},
   article_number = {January},
   doi = {https://doi.org/10.1016/j.canlet.2021.10.037},
   keywords = {p53; Sarcoma; Mesenchymal stem cells; Cancer stem cells; p53-targeted therapy},
   language = {eng},
   issn = {0304-3835},
   journal = {Cancer letters},
   title = {Noncanonical roles of p53 in cancer stemness and their implications in sarcomas},
   url = {https://www.sciencedirect.com/science/article/pii/S030438352100553X?via%3Dihub},
   volume = {525},
   year = {2022}
}

TY  - JOUR
ID  - 1807837
AU  - Curylová, Lucie - Ramos, Helena - Saraiva, Lucília - Škoda, Jan
PY  - 2022
TI  - Noncanonical roles of p53 in cancer stemness and their implications in sarcomas
JF  - Cancer letters
VL  - 525
IS  - January
SP  - 131-145
EP  - 131-145
PB  - Elsevier Ireland Ltd
SN  - 03043835
KW  - p53
KW  - Sarcoma
KW  - Mesenchymal stem cells
KW  - Cancer stem cells
KW  - p53-targeted therapy
UR  - https://www.sciencedirect.com/science/article/pii/S030438352100553X?via%3Dihub
N2  - Impairment of the prominent tumor suppressor p53, well known for its canonical role as the "guardian of the genome", is found in almost half of human cancers. More recently, p53 has been suggested to be a crucial regulator of stemness, orchestrating the differentiation of embryonal and adult stem cells, suppressing reprogramming into induced pluripotent stem cells, or inhibiting cancer stemness (i.e., cancer stem cells, CSCs), which underlies the development of therapy-resistant tumors. This review addresses these noncanonical roles of p53 and their implications in sarcoma initiation and progression. Indeed, dysregulation of p53 family proteins is a common event in sarcomas and is associated with poor survival. Additionally, emerging studies have demonstrated that loss of wild-type p53 activity hinders the terminal differentiation of mesenchymal stem cells and leads to the development of aggressive sarcomas. This review summarizes recent findings on the roles of aberrant p53 in sarcoma development and stemness and further describes therapeutic approaches to restore normal p53 activity as a promising anti-CSC strategy to treat refractory sarcomas.
ER  -

CURYLOVÁ, Lucie; Helena RAMOS; Lucília SARAIVA a Jan ŠKODA. Noncanonical roles of p53 in cancer stemness and their implications in sarcomas. \textit{Cancer letters}. Elsevier Ireland Ltd, 2022, roč.~525, January, s.~131-145. ISSN~0304-3835. Dostupné z: https://doi.org/10.1016/j.canlet.2021.10.037.

Přehled o publikaci